David Martin PhD, an analyst from Bloom Burton, has initiated a new Buy rating on Conavi Medical (CNVIF).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Martin PhD has given his Buy rating due to a combination of factors that highlight Conavi Medical’s promising future. The company is on the brink of a significant milestone, as it is poised to secure FDA clearance for its innovative Novasight Hybrid System by the first half of 2026. This system is noteworthy because it integrates two prevalent intravascular imaging technologies, namely intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
The anticipated FDA approval and subsequent launch of the Novasight Hybrid System are expected to propel Conavi Medical’s market position and drive substantial growth. With a projected 156% increase in stock value from its current price, the potential upside offers an attractive investment opportunity. These strategic advancements and the expected market impact underpin David Martin PhD’s positive outlook and Buy rating for Conavi Medical.